News More good news in Sjogren's as RemeGen trial delivers A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.
News Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen After winding up its stem cell therapy operations last month, Vor Bio has reinvented itself as an autoimmune disease-focused biotech.
News Vor Bio winding down as multiple biotechs downsize Biotech pressures exposed as big job losses are announced at Vor Bio, IGM Biosciences, Rallybio, Insitro, and Korro Bio.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
